Drug Trial Radar · NCT03702855
Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed Conditions
Last checked: Nov 20, 2026Latest source record: Oct 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Dec 2015
Primary completion
Dec 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- Dr. Reddy's Laboratories Limited, IndiaIndustry
- Sponsor type
- Industry
- First posted
- Oct 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, randomized, four-period, two-treatment, two-sequence, balanced, single dose, crossover, oral bioequivalence study in healthy, adult, human subjects under fed conditions.
Conditions
- Healthy
Interventions
Tetrabenazine Tablets 25 mgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under curveTime frame: Pre-dose (within 1 hour prior to dosing), 0.33, 0.67, 1.00, 1.33, 1.50, 1.75, 2.00, 2.50, 3.00, 3.50, 4.00, 5.00, 6.00, 24.00 hours post dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Accutest Research Laboratories (I) Pvt. Ltd.
Navi Mumbai, Maharashtra, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.